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Abstract
Living donation is still needed to overcome organ shortage. All countries seem 
to increase and encourage such kind of donation according to medical and ethi-
cal guidelines. The results of renal transplantation from living donors are better 
compared to those from cadaveric kidneys. Since the first successful kidney trans-
plantation from a living donor, some 63 years ago, surgery has shifted toward a less 
invasive approach offering to the donor less pain, better cosmesis, a shorter hospital 
stay, and a quick return to normal activities. Laparoscopic living-donor nephrec-
tomy (LLDN) is now considered as the gold standard approach for kidney retrieval 
on live donors and has undoubtedly revolutionized kidney donation. It must offer 
to the donor safety, low morbidity, and fast recovery and must obtain a graft with 
adequate vessel length, short warm ischemia time, and well-preserved ureteral 
blood supply. We describe our technique of LLDN according to safety principles 
and reproducible steps. Highly qualified and well-trained surgeons are allowed to 
perform such techniques within a very well-equipped environment and with expe-
rienced surgical staff. A living donor program should undertake at least 30 cases per 
year to maintain adequate experience and offer less complication rate.
Keywords: live donor, laparoscopy, nephrectomy, kidney transplantation,  
living kidney donation
1. Introduction
Living kidney donation has successfully improved the lives of many patients 
worldwide for over half a century. Do we still have the same need for living donors 
in 2018? The answer is obviously yes and for many reasons. The first is organ 
shortage with a widening gap between renal supply and demand in all countries 
that increases every year despite the use of marginal deceased donors. Waiting 
lists are growing everywhere. The site of the US Government Information on 
Organ Donation and Transplantation, organdonor.gov, shows recently a transplant 
waiting list of more than 114,000 patients of whom 83% are potential kidney 
recipients [1]. The second reason is the significant graft survival advantage and 
the reduction of the waiting time between end-stage renal disease and graft 
implantation. The results of renal transplantation from living donors are  better 
compared to those from cadaveric kidneys with a graft half-life of 18 versus 
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12 years, respectively [2]. Kidney transplantation from a living donor, when 
possible, is the best treatment for most patients with end-stage renal disease. 
This is related to multiple factors such as less time from dialysis to transplanta-
tion, shorter cold ischemia time, and better quality of the graft. The third reason 
stands for pediatric recipients where a prompt transplantation from a living donor, 
mostly a parent, can help for a better growth, quick return to school, and a good 
psychological stability; it is considered today as the gold standard therapy for 
children with end-stage renal disease. The fourth argument is that living donation 
provides a good opportunity to perform a preemptive transplantation avoiding the 
need of going through dialysis. A fifth reason is that we are still too far to over-
come organ shortage by using xenografts from transgenic animals, or engineered 
organs from stem cells.
Currently, 40% of kidney grafts in the United States are from living donors [1]. 
In Europe, the level is highly variable between countries, standing for approxi-
mately 10% in France and up to 60% in Norway and Sweden [2, 3]. Approximately, 
one in three kidney transplants performed in the UK are from living donors [4], and 
according to the Global Observatory on Donation and Transplantation (GODT), 
84,347 kidney transplants were done worldwide in 2015, of which 41.8% were from 
living donors [5].
In some countries, namely Middle Eastern and Eastern, kidney transplantation 
is relying only or mostly on living donors [6, 7]. Worldwide kidney transplant from 
living donors in 2017, based on the International Registry in Organ Donation and 
Transplantation, is shown in Figure 1 [8].
Women traditionally outrank men in their enthusiasm to donate one of their 
kidneys. Although most recipients are male, women represented 63% of all living 
donations in 2016 [9].
In regard to these facts, living donors have exceptional courage and nobility; 
they go through a major surgery, accepting all surgical and medical risks and of no 
medical and physical benefit for them. It is our vocation and duty to provide them 
a safe and good practice according to legal and ethical bylaws and to protect their 
health in the long term.
2. Historical milestones
The first true altruistic voluntary living donation happened in Paris at Necker 
Hospital on December 25, 1952, when a mother, Gilberte Renard, convinced the 
medical team to give her kidney to her son Marius, 16 years old, apprentice car-
penter who had his right solitary kidney removed after falling from a scaffolding. 
Unfortunately, the graft remained functional for approximately 3 weeks despite the 
Figure 1. 
Worldwide kidney transplant from living donors in 2017. International Registry in Organ Donation and 
Transplantation.
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use of steroids and Marius died on January 27, 1953. His donating mother died in 
1992 at age 85 [10, 11].
The second important milestone happened 1 year later on December 23,1954 at 
Brigham Hospital in Boston USA, when Dr. Murray performed a successful renal 
transplantation on Richard Hersick, the donor being his monozygotic identical twin 
brother Ronald. The kidney was removed from Ronald by the urologist Harrison. 
No effort was made to preserve the isograft; but nonetheless, it functioned 
promptly despite 82 min of warm ischemia [12]. The graft remained functional for 
8 years and was lost due to a recurrence of the renal disease and causing the death 
of Richard. His brother Ronald died in 2010 at age 79, after a cardiac surgery, just 
4 days after the 56th anniversary of his pioneering kidney operation [11, 13].
The next two following years, the Brigham team performed seven successful 
kidney transplants also between identical twins. The most famous was that of Edith 
Helm, the third case at Brigham, who got pregnant 2 years after her transplant and 
was the first kidney recipient to carry to term and give birth to a child. Edith Helm 
also holds the record of the best graft longevity of 55 years; she died in 2011 at age 
76, with a functioning graft. Her donating identical twin sister, Wanda Foster, gave 
birth three times following her kidney donation and was still alive in 2016 [11, 14].
In 1960, the first kidney transplantation between genetically nonrelated 
patients was performed using immunosuppression. Late in 1963, a conference near 
Washington DC was held to present the overall findings from 216 recipients of renal 
allografts. The results were not gratifying: 52% of all those receiving grafts from 
related donors had died, and 81% of those with kidneys from unrelated or cadaveric 
donors. Joseph Murray concluded at that time that “kidney transplantation is still 
highly experimental and not yet a therapeutic procedure.” By 1965, 1 year survival 
rates of allografted kidneys from living related donors were much better approach-
ing 80%, due to better immunosuppression [12, 15].
In 1987, Alexandre et al. in Belgium published a first series of ABO-incompatible 
(ABO-I) living donors using splenectomy and heavy immunosuppressive regimen 
in the recipient. Results were fairly optimal [16].
Then, since 1989 and due to organ shortage, most ABO-I kidney transplanta-
tions have taken place in Japan with recently published data showing an excellent 
long-term outcome. Currently, ABO-I reached approximately 30% of all living 
donor renal transplantation in Japan [17, 18].
From the surgical point of view, all donor nephrectomies were done by open 
techniques mostly using a lumbar retroperitoneal approach; and the first successful 
trial of removing a live donor kidney using a laparoscopic approach was in 1995 at 
John’s Hopkins hospital by Ratner et al. [19]. Since then, considerable numbers of 
transplant centers worldwide have adopted laparoscopic donor nephrectomy (LDN) 
which is now considered as the gold standard approach for kidney retrieval on live 
donors and has undoubtedly revolutionized kidney donation.
3. Living donor evaluation
Suitability of the potential kidney recipient for transplantation must be estab-
lished before starting donor assessment. There is a significant variability among 
transplant programs in the criteria used to evaluate donors. ABO blood grouping is 
an important early screening test. Initial assessment of donor and recipient histo-
compatibility status must be undertaken at an early stage in living donor kidney 
transplant workup to avoid unnecessary and invasive clinical investigation [4]. 
Although donors are not true patients, they must undergo a complete and extensive 
evaluation before considering kidney removal. This evaluation includes medical and 
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surgical past history, risk factors like alcohol intake and smoking, family history 
(mainly renal disease, hypertension, and diabetes), renal, liver, and cardiopulmo-
nary function. They should have no active malignancy or infection. The waiting 
period before transplant in recipients with a history of malignancy depends on the 
type, TNM stage and grade of the tumor, and recipient’s age and general health. 
Recipients with tumors that have a low recurrence rate can be considered for imme-
diate transplantation after successful treatment. Active HBV and HCV are usually 
contraindications to living donor kidney donation; and HIV infection is an absolute 
contraindication. Screening of serum prostate-specific antigen (PSA) is mandatory 
in males above 54 years as also mammograms in women. A urine albumin/creatinine 
ratio done on a spot urine sample is a recommended screening test and it should be 
<30 mg/mmol. The presence of persistent microhematuria (two or more positive 
urine analysis) or recently called “persistent nonvisible hematuria,” with no evident 
explanation like stones, neoplasms, and infection, should be investigated with cys-
toscopy and renal biopsy. Assessment of renal function is based on serum creatinine 
and calculation of creatinine clearance. Differential kidney function, using DMSA 
isotope scanning, is recommended when there is >10% variation in kidney size or 
abnormal renal anatomy [4]. Donors with mild and well-controlled hypertension, 
on one or two antihypertensive drugs, and with no evidence of end organ damage 
(retinopathy, left ventricular hypertrophy, proteinuria), might be accepted [20]. 
Data regarding long-term safety of nephrectomy in hypertensive donors are modest; 
but small studies with short-term follow-up suggest no increase in the incidence of 
kidney disease or worsening of the control of hypertension in donors with a his-
tory of mild well-controlled hypertension [21]. The Amsterdam Forum consensus 
guidelines in 2004 stated that some patients (age > 50, GFR >80, and with low urine 
albumin excretion of <30 mg/d) with easily controlled hypertension can represent 
a low-risk group for the development of kidney disease but might be considered 
as donors [22]. A psychosocial assessment is recommended for all donors with 
appropriate referral to a mental health professional who can be a psychologist or a 
psychiatrist. This assessment also evaluates whether the decision to donate is free of 
constraint and other undue pressures. Donor age is suggested to be between 22 and 
75 years; but the upper age limit can be beyond if the donor is in good health and 
with a normal range of age-related change in kidney function (e.g., advisory thresh-
old GFR levels considered acceptable at age 80 years is 58 ml/min/1.73 m2 for males 
and 49 ml/min/1.73 m2 for females). A safe threshold level of predonation kidney 
function is one that leaves sufficient function after donation to maintain the donor 
in normal status without affecting lifespan [4]. Old donors (> 60 years) should be 
aware of a greater risk of pre- and postoperative complications. We are very cautious 
about young donors who are less than 30 years old because their absolute risk over 
a lifetime, particularly with additional risk factors for end-stage renal disease (like 
hypertension, obesity, and diabetes), is likely to be more significant [4]. Living 
donors should ideally have a body mass index (BMI) that is less than 30 kg/m2. Data 
on the safety of kidney donation in the very obese (BMI >35 kg/m2) are limited and 
donation should be discouraged. Morbid obesity increases the risk of hypertension, 
dyslipidemia, insulin resistance and diabetes, heart disease, stroke, sleep apnea, and 
certain cancers [23]. On the other hand, data suggest that laparoscopic living-donor 
nephrectomy (LLDN) is an increasingly safe procedure in the otherwise healthy 
obese kidney donor and does not result in a high rate of major perioperative compli-
cations [24, 25]. Also, transplantation from an old or obese donor is most probably 
better than dialysis or transplantation from a deceased donor [26]. Computed 
tomography and tomographic angiography are used to assess renal vascular anatomy 
(presence of accessory vessels, intervessel distance, distance from ostium to the 
first division, presence of atherosclerotic disease), renal dimensions, presence of 
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stones, urinary tract anatomy, and the existence of any suspicious lesion not seen 
on ultrasound. Around 25% of will have multiple arteries to one kidney and 7% 
will have multiple vessels to both kidneys [27]. Renal pedicles with less than three 
arteries are accepted.
The presence of multiple renal cystic lesions in a potential living kidney donor 
requires careful evaluation and a detailed family history; in those with a family his-
tory of polycystic kidney disease under the age of 40 years, the presence of two or 
more cysts (unilateral or bilateral) indicates autosomal dominant polycystic disease 
(ADPKD) and exclude donation [28]. For those aged 40–59 years, the absence of at 
least two cysts in each kidney gives a 100% negative predictive value for ADPKD, 
while for those older, up to four cysts are acceptable in each kidney [4]. History or 
current presence of bilateral renal stones is a contra indication for donation; but in 
some centers, donors with a history of nephrolithiasis are accepted as long as stones 
are no longer present and metabolic studies are normal [29].
4. Surgical technique
Multiple techniques have been described to harvest a kidney from a living donor. 
The old classic open surgery performed through a lumbar or subcostal incision is 
nowadays much less popular compared to mini-invasive approaches using laparo-
scopic extra corporeal manipulation and magnified ultrahigh definition view of the 
surgical field. But regardless of how minimally invasive laparoscopy can be, living 
donor nephrectomy remains a maximally invasive surgery because we are dealing 
with major vessels and consequently very serious and sometimes lethal hemorrhagic 
complications might occur. Highly qualified, competent, and well-trained surgeons 
are allowed to perform such techniques within a very well-equipped environment 
and with experienced surgical staff. A living donor program should undertake at 
least 30 cases per year to maintain adequate experience. Today, laparoscopy is by far 
the preferred procedure for kidney removal in live donors, offering a quick recovery, 
less pain, and a shorter hospital stay; and it will be the technique detailed in this 
chapter. A well-informed consent is obtained prior to surgery. The surgeon perform-
ing living donor nephrectomy has a particular responsibility to ensure that the donor 
fully understands the potential risks and long-term effects of the operation. Surgery 
must offer to the donor safety, low morbidity, and fast recovery; and must obtain 
a graft with adequate vessel length, short warm ischemia time, and well-preserved 
ureteral blood supply. A donor kidney with a single renal artery should, whenever 
possible, be chosen for transplantation to minimize the risk of vascular complica-
tions in the recipient procedure; similarly, single renal veins are usually preferred. 
Many transplant centers prefer the left kidney for LLDN because of the longer vein 
and perhaps an easier surgery on the left side; but with increasing experience, kid-
ney side was not a real obstacle [30] although for some authors the right kidney was 
the only risk factor for early graft thrombosis [31, 32]. The answer to which kidney 
to take when facing a donor with two arteries on the left and a single artery on the 
right is based on the surgeon’s experience of laparoscopic right nephrectomy and his 
skills in reconstructing the vasculature of the graft. The presence of a retroaortic 
renal vein is of no problem with no increased complications; and it is even an easier 
case because of the large distance between the artery and the retroaortic vein which 
is in an inferior position (Figure 2). The most important criterion regarding the side 
to be chosen for retrieval is to keep the better kidney for the living donor.
There is variability among different centers on the choice of laparoscopic tech-
nique between only pure laparoscopy (transperitoneal versus retroperitoneal), only 
hand-assisted laparoscopy or a combination of both. Laparoendoscopic single-site 
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surgery (LESS), natural orifice transluminal endoscopic surgery (NOTES), and 
robotic-assisted are other interesting techniques that still need to be evaluated. 
In our experience, we started our first 10 cases with hand assistance, given the 
increased security that it provides, and then switched to pure transperitoneal 
laparoscopic approach which will be detailed in this chapter.
4.1 Anesthesia
Laparoscopic donor nephrectomy has had a big impact on anesthesia and 
recovery of this special category of patients. Intraoperative anesthesia for lapa-
roscopic live donors follows the rules of laparoscopic kidney surgery as far as 
sedation and muscle relaxation but the concept of protection of the donor kidney 
is mandatory throughout the case, one among many disparities compared to other 
kidney surgeries [33]. Nowadays, two large-bore IV catheters are considered more 
than enough as far as vascular access and risk of bleeding. Arterial lines are not 
recommended and noninvasive blood pressure monitoring is a reasonable option 
[34]. After induction of anesthesia, classically with propofol and a neuromuscular 
blocking agent, maintenance of anesthesia has been the subject of many studies 
to evaluate the nephrotoxicity of various agents. While isoflurane and desflurane 
were considered safe and with the least toxicity on the kidney, this was not the 
case with sevoflurane that is associated with production of compound A in the 
circulation; a direct nephrotoxic substance [35]. Despite many works, the type of 
anesthetic agent was not shown to impact serum creatinine or GFR in transplanted 
grafts and it was concluded that toxicity, if any, was minimal. Nitrous oxide is one 
agent preferably avoided in laparoscopic surgery as it can cause bowel distention 
in more than 50% of cases and subsequent compromise of insufflation or surgical 
field exposure in near 25% of laparoscopic donor nephrectomy, increasing the need 
even more for neuromuscular blocking agents [36]. Mechanical ventilation set-
tings are not different from other laparoscopic procedures. Special considerations 
for donor nephrectomy would include tolerance of mild hypercapnia to 45 mmHg 
since it helps better tissue perfusion and circulation in light of pneumoperitoneum. 
Positive-end expiratory pressure (PEEP) at 5–10 mmHg, a 20–30% increase in 
minute ventilation reflecting an increased respiratory rate with constant volumes, 
is similar to other laparoscopic procedures. The effects of pneumoperitoneum were 
explored by studies on rats demonstrating that abdominal insufflation with CO2 
during laparoscopy in subjects with chronic renal function impairment should not 
be a contraindication to surgery [37]. Additionally, if insufflation had a substantial 
negative effect on kidney function, we would have expected this to have a great 
impact on kidney donors out of concern on the retained kidney, which has not been 
Figure 2. 
Retroaortic vein (V). See the distance between the artery (A) and the vein (V). U = ureter.
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born out in the literature. IV hydration holds a crucial place in counteracting the 
notorious effects of pneumoperitoneum on tissue perfusion and renal plasma flow 
caused by an increased intraperitoneal pressure sometimes near 15 mmHg. Some 
studies emphasized the great effects of hydration on mean arterial pressure preser-
vation and ensuring hemodynamic stability [38]. Whether this is realized by giving 
donors colloid boluses preoperatively or during surgery is based on institutional 
protocols and the team preferences. In general, a patient undergoing laparoscopic 
donor nephrectomy should get 4–6 L during the procedure to maintain at least a 
urine output >50 mL/h [38]. This will help avoid the use of any vasopressors or 
inotrope agents because of the associated deleterious renal vasoconstriction. If 
they become really needed, ephedrine is the best agent to start with, giving small 
boluses in order to attain the desired effects. IV fluids should be warmed and full 
measures should be taken to prevent hypothermia. There is a mounting evidence 
to suggest that 0.9% normal saline can be detrimental to patient outcome, and may 
indeed contribute to renal dysfunction, and therefore, the use of this solution in 
donors cannot be recommended; Ringer’s lactate solution is the intravenous fluid of 
choice [4]. The administration of mannitol 12–25 g once or twice, or furosemide at 
small doses during the case, is another example of common practice depending on 
departmental protocols, but they lack any definite data or evidence to support it.
4.2 Antibiotics, patient position, and trocar placement
We routinely give antibiotic prophylaxis based on one single shot of cefazolin. 
After placement of a Foley catheter, the patient is put in a complete lateral decubitus 
position almost 90° to the table without any flexure or kidney rest; the belly being 
on the external border of the table. Arms and legs are well secured with pillows 
and gel pads to prevent any vascular or nerve compression. We start by doing the 
extraction site as a small transverse supra pubic incision 6–8 cm width, depending 
on donor kidney size, with opening of the peritoneum and insertion of a LapCap 
device (Applied Medical-Alexis Laparoscopic System with Kii® Fios® First Entry) 
(Figure 3 and Video 1 (https://youtu.be/LBWXDCD2Upk)). Pneumoperitoneum 
induction is made through this device. Intraabdominal CO2 pressure is fixed at 
12 mm Hg. The use of low-pressure pneumoperitoneum with deep neuromuscular 
block did not seem to reduce postoperative pain scores or improve the overall qual-
ity of recovery after surgery [39]. After complete insufflation, we insert all trocars 
under direct vision. On the left side, the first is a 10 mm placed umbilical or para 
umbilical depending on obesity status; the second is a 5 mm placed subcostal on the 
level of the anterior axillary line, and the third one is a 12 mm trocar (which comes 
in the LapCap package) placed in the left iliac fossa (Figure 3). On the right side, 
Figure 3. 
Left side: position of patient and 3 trocar placement: 5 mm subcostal, 10 mm umbilical or para umbilical 
(yellow dot) depending on obesity, and 12 mm left iliac fossa. LapCap device shown on the right.
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trocar placement is the same with an additional 5 mm one, inserted at the xiphoid 
for liver retraction. Additional ports can be used in some rare difficult cases and 
sometimes we do percutaneous kidney suspension using a 2/0 silk on a straight 
needle through Gerota’s fascia and perirenal fat (Figure 4).
4.3 Surgical steps
As described in all transperitoneal approaches, we start by taking the colon off 
the kidney medially along the Toldt’s fascia from the iliac vessels up to the colonic 
angle (splenic flexure on the left and hepatic flexure on the right). Gerota’s fascia 
is left intact on the kidney (Figure 5). The lateral and parietal attachments of the 
kidney are left in place to prevent the kidney from slipping down and disturb-
ing later the hilar dissection. We use from the start a LigaSure™ Maryland 5 mm 
(Covidien) sealing device. We then dissect and isolate the ureter inferiorly down 
to the iliac vessels with identification of the psoas muscle and the genital vessels. 
All periureteral and inferior renal pole fat must be well preserved to keep a well-
vascularized ureter (Figure 6). Avoid any injury to the genitofemoral nerve and 
try to keep the psoas fascia in place. The gonadal vein can be divided proximally 
and distally and kept with the ureter in order to protect ureteric vascularity. This 
is thought to be the cause of postoperative ipsilateral orchialgia, which occurs in 
6.2–9.6% of male donors [40, 41]. Large studies, however, have demonstrated that 
leaving the gonadal vein in situ does not lead to increased ureteric complications in 
the transplant recipient [42] and prevents orchialgia [40, 43].
4.3.1 Left-sided nephrectomy
The ureter and its peri ureteral fat are lifted up to undertake an upper dissection 
along the genital vein until we reach the inferior border and the anterior aspect of the 
renal vein (Video 2 (https://youtu.be/Ms38M9mIV0Q)). Then, the spleen and tail of 
the pancreas are completely mobilized by cutting the splenorenal and splenophrenic 
ligaments (Video 3 (https://youtu.be/lKNHPx66Mgo)). Care is taken not to injure the 
pancreas, the splenic artery, and the stomach near the level of the crus of the dia-
phragm where dissection ends. By achieving this step, the space between the spleen and 
the kidney is usually widely opened and permits partial mobilization of the upper renal 
pole (Figure 7). We then proceed to adrenal dissection and separation starting very 
carefully from the upper border of the renal vein toward the upper pole of the kidney 
with division of the adrenal vein using LigaSure sealing without any clip placement and 
caring not to injure the anterior branch of the renal artery or small upper pole accessory 
Figure 4. 
Left kidney suspended with a 2/0 silk suture on the parietal wall.
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arteries not detected on the preoperative renal angio CT scan (Video 4 (https://youtu.
be/WbgzAzZZprk)). This step will almost complete the upper pole release.
The renal pedicle is now ready to be dissected. Before starting the hilar dissec-
tion, 12–25 mg of mannitol is administered. All lymphatics and autonomic nerve 
plexuses superior to the vein and around the renal artery are sealed and cut. Some 
small segments of these structures are sometimes difficult or possibly dangerous 
to access, and in such a case, they are quickly sealed and cut after the stapling of 
the renal pedicle. Very careful and minutious dissection is undertaken between 
the artery and vein to prepare a clear, precise, and secure positioning of the sta-
pling device. The left renal artery is dissected at its aortic origin (Video 5 (https://
youtu.be/5wyqkJz7ick)). If vasospasm is noted, the renal artery can be bathed in a 
papaverine solution (30 mg/ml) [44]. In some cases, retroperitoneal veins (lumbar, 
ascending lumbar, and hemiazygos) join the left renal vein in up to 75% of indi-
viduals, and it must be sealed and cut [45]. Clips are avoided on all venous branches 
Figure 5. 
Left renal aspect after colon dissection. Gerota’s fascia is left intact.
Figure 6. 
Ureter with well-preserved periureteral fat and vasculature.
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to prevent their later insertion between the jaws of the stapling device leading to 
misfire and serious malfunction [46].
The ureter and its periureteral fat are again lifted up at the level of the iliac 
vessels and posterior dissection will start from here and go up to the whole posterior 
surface of the kidney. The ureter is isolated with a generous periureteric fat. After 
completing this posterior release, the kidney is completely lying medially and we 
can free the posterior aspect of the renal artery (Figure 8; Video 6 (https://youtu.
be/xQswiMds4Nc)). Now the kidney is supposed to hold only on the artery, vein, 
and ureter and is ready to be harvested. The patient is given another dose of man-
nitol. An Endocatch bag 15 mm (Covidien) is inserted through the LapCap. The 
distal ureter is clipped and sectioned. A good flow of urine should be noticed before 
pedicle clamping. A number of vascular transfixing stapling devices are available 
for surgeons to secure the renal vessels. The choice of which device to use is down to 
surgeon preference. Recently, we rely on two stapling devices: Endo-TA 30 stapler 
(30-mm length, 2.5-mm staples-Covidien) if maximum length is needed because 
this device delivers three rows of staplers without a cutting knife and no articula-
tion; and vessels are cut with cold scissors; and Echelon Flex™ Powered Vascular 
Stapler 35 mm (Ethicon) with manual articulation for more precise placement, a 
narrow curved blunt tip, and reduction in tip movement during firing; this device 
delivers four rows of staples (instead of six) in a staggered pattern and gives a very 
secure vascular control and less loss in vessel length with nonbloody surgical field 
because of the absent backflow. Stapling starts on the renal artery and then quickly 
on the vein, and the kidney is rapidly placed in the Endo bag and extracted through 
the LapCap (Videos 7 (https://youtu.be/RfIGOjtqpD8) and 8 (https://youtu.be/
dGUKd3R23Yo)). We do not give intravenous heparin prior to vascular occlusion. 
Figure 7. 
Spleen separated from the left renal upper pole.
Figure 8. 
Laparoscopic view after posterior left renal dissection.
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Warm ischemia time is usually around 3–5 min before the kidney is flushed out on 
ice with the preservation solution.
Originally, the artery was secured using locking polymer clips that are much 
cheaper than staples. On April 2006, the manufacturer of Weck Hem-o-lok ligating 
clips, Teleflex Medical, added a contraindication to the use of these clips on renal vessels 
in laparoscopic live donor nephrectomy, after receiving 15 medical device reports of 
12 injuries and 3 deaths, all of which occurred between November 19, 2001 and March 
20, 2005. All reports were associated with using the clips for ligation of the renal artery 
during LLDN [47, 48]. Clip dislodgement may occur several hours following the proce-
dure resulting in fatal hemorrhage on the ward [49]. US Food and Drug Administration 
(FDA) issued on May 2011 a warning to healthcare providers that Weck Hem-o-Lok 
ligating clips should not be used for the ligation of the renal artery during LLDN 
because of serious risks and potential life-threatening complications to the donor [50]. 
On the other hand, surgeons must be aware that reported failure rates for staplers are 
3.0% [51]. Stapler misfire rates can be reduced by avoiding the use of titanium and 
other clips around the hilar structures before securing the renal pedicle [46].
Before ending the surgery, latero aortic and inter aorto caval lymphatics are 
clipped (Hem-o-lok clips) to prevent chylous leakage (Video 9 (https://youtu.be/_
c4rjTtvlTw)). Meticulous and extensive clipping remains the safest way of securing 
lymphatic channels along the dissection area despite being usually burned with 
energy-based sealing devices. It has been shown that bipolar cautery can effectively 
ligate and control lymph leakage as also other laparoscopic dissection devices using 
bipolar and ultrasonic energy but monopolar scissors were unreliable with respect 
to sealing lymphatic channels [52, 53]. Last view of the whole surgical field is done 
with particular inspection of the vascular stumps (Figure 9). Pneumoperitoneum is 
exsufflated. No drainage is usually needed. Port and extraction sites are closed.
4.3.2 Right-sided nephrectomy
In some patients, the right side seems to be easier than the left. Steps are almost 
the same. Trocar placement has the same distribution as on the left except for an 
additional 5 mm trocar inserted at the xiphoid for liver retraction (Figure 10). Less 
right colon dissection is needed and careful duodenal displacement is performed to 
expose the inferior vena cava (IVC). Genital vein is usually kept in place. The renal 
upper pole is carefully separated from the adrenal as on the left side starting from 
the upper border of the right vein. Renal vessels are also approached from below 
after isolation of the ureter and periureteral fat and identification of the psoas 
muscle and lifting up the kidney. The right renal vein is exposed at its insertion into 
Figure 9. 
Left renal artery and vein stumps after stapling and kidney harvesting. Clips on lymphatics are placed after 
vascular stapling.
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the IVC. Duplication of renal vein is more common on the right side and is reported 
in as much as 15% of potential renal donors [54] (Figure 11). The adrenal vein, 
gonadal vein, and retroperitoneal veins (lumbar, ascending lumbar, and hemiazy-
gos) may drain into the right renal vein in 30, 7, and 3% of cases, respectively [55]. 
The IVC must be well dissected below and above the renal vein to permit later easy 
positioning of the stapler device. In usual anatomy, the renal artery is classically 
found just behind the vein and the space between artery and vein is normally easily 
created. Retrocaval area is a difficult area to work at during LLDN; therefore, the 
exact location of the first segmental branch of right renal artery with respect to the 
IVC should be clearly identified in the pretransplant angio CT scan. In some cases, 
posterior release of the artery behind the IVC is necessary to reach the main trunk 
(Video 10 (https://youtu.be/DPGFtpAVar8)) especially if the artery is in an upper 
position to the vein (Video 11 (https://youtu.be/BfbPdO-U8zU)); or even rarely, 
access to the artery is done through the inter aorto caval space. Caval countertrac-
tion is applied just prior to firing the endovascular stapler, so that adequate venous 
length is obtained. The renal vein is usually 2–3 mm shorter compared with the open 
surgery. Operative time and warm ischemia time may be greater when performing a 
right-sided LLDN, but this does not result in delayed allograft function [56].
5. Postoperative care
The early postoperative period after laparoscopic donor nephrectomy is a 
particular moment in the management of kidney donors. Extubation is done after 
Figure 10. 
Liver retracted through a 5-mm xiphoid trocar.
Figure 11. 
Laparoscopic view of right donor kidney with two veins (V) and one artery (A).
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normothermic state. Orogastric tube is removed prior to extubation. Hemoglobin 
measurement is realized every 6 h postsurgery, and if normal, it will be repeated the 
next morning with serum creatinine and electrolytes. Urine output is monitored. 
Shoulder tip discomfort and pain is a major complaint after LLDN perhaps from 
residual pneumoperitoneum. Epidural analgesia is ineffective for shoulder pain. 
There has been collective belief to aggressively minimize pain postoperatively in this 
special category of patients who are usually narcotics naïve. IV “patient-controlled 
analgesia” (PCA; fentanyl or morphine less commonly) was considered to be the 
modality of choice to achieve that. If PCA is not available, pain control is achieved 
with IV paracetamol and if needed ketoprofen or ketorolac over the first 24 h [57]. To 
reduce the risk of nephrotoxicity, the patient should be kept well hydrated. Opiates 
also have an effective role for breakthrough pain when opiate-sparing strategies have 
not been effective. Clear liquids are started on the day of surgery with increase of 
diet later. The emergence of enhanced recovery after surgery (ERAS) brought major 
changes to the traditional standard of care. Many centers across the USA have adopted 
the enhanced recovery programs that include intraoperative fluid restriction to 3 ml/
kg/h preventing excessive third spacing and bowel edema, urine output of 0.5 ml/
kg/h, use of local subfascial bupivacaine or other anesthetics as well as a postoperative 
narcotic-free pain control regimen, i.e., acetaminophen, ketorolac, etc. [58]. Novelties 
in this management were associated with reduced length of hospital stay, better pain 
control, and increased patient satisfaction. It has become evident that ERAS would 
potentially enhance the benefits of laparoscopic surgery for kidney donors [59].
Foley catheter is removed on the morning of day 1 and ambulation started as 
soon as possible either during the evening of day 0 or the next morning. Living 
kidney donors are classified as “medium risk” patients for deep venous thrombosis 
(DVT) and pulmonary embolism [4]. All living donors must have intra- and post-
operative compression stockings and should receive adequate thromboprophylaxis 
with low-molecular weight-heparin and continuing for at least 1 week. Patient is 
discharged most frequently on day 2 and seen back 10 days later with a follow-up at 
6 months, 1 year, and 2 years after donation. Donors must resume a normal life-
style as soon as possible with regular surveillance of their blood pressure and their 
weight. They should be warned about avoiding nephrotoxic medications.
6. Complications
LLDN appears to be a safe procedure or at least as safe as the open one. But 
serious complications including death may occur. Overall mortality rate is approxi-
mately 0.03% [34] although some large series reported no mortality [60–63]. 
Most of these deaths occurred in the postoperative period and were due to hemor-
rhage [47], CO2 gas embolism [64], and pulmonary embolism [34]. The risk of 
a major intraoperative hemorrhage during LLDN is between 0.6 and 1.6% [60, 
63]. Conversion to open surgery has been reported to occur in 0 to 13% of cases, 
but in most large series, conversion rates of 1–2% are reported [4, 60–63]. Other 
intraoperative complications are splenic or liver laceration, ureteral and intestinal 
injury, and pleural laceration. The total incidence of surgical complications is 5.46% 
[61]. All major complications occurred in the first 100 cases [62]. This raises the 
question of the learning curve and how many laparoscopic nephrectomies should 
be done before performing the first LLDN? There is no precise answer but a number 
between 50 and 100 seems to be convincing for this type of surgery to be learned.
Postoperative complications of LLDN are hematomas, fever, urinary tract 
infection, pneumonia, pulmonary embolism, wound infection, incisional hernias, 
prolonged ileus, chylous ascites, and left testicular pain perhaps due to gonadal vein 
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division or extensive mobilization of the left colon which may damage the neural 
plexus supplying the testis and may also disrupt lymphatic drainage [65]. Chylous 
leakage is a rare complication of LLDN. Prevention is assured by doing a meticulous 
and extensive clipping of lymphatic channels along the dissection area [52, 66].
Long-term complications are arterial hypertension, renal failure, and protein-
uria, particularly in more high-risk donors, such as those with obesity, old or young 
donors, hypertensive donors, and those with kidney stones [67, 68]. Following 
kidney donation, there is a compensatory increase in function in the remaining 
kidney. By 3 months, remnant kidney clearance increases to a mean GFR of around 
65–75% of predonation renal function [4]. The average decrease in GFR after dona-
tion was 26 mL/min/1.73 m2 (range 8–50) [4, 69]. The incidence of end-stage renal 
disease (ESRD) in living kidney donors appears to be similar to or lower than that 
seen in the unselected general population despite a reduction in GFR [4, 24, 70]. 
The estimated lifetime risk of ESRD was 90 per 10,000 in donors, 326 per 10,000 in 
the general population, and 14 per 10,000 in matched healthy nondonor controls 
[71]. Live donor nephrectomy alone will not lead to renal failure [72].
Concerning hypertension, a large meta-analysis demonstrated that donors have 
an increased systolic blood pressure of 5 mmHg after 5–10 years from donation 
[73]. The rate of hypertension in donors was similar to that of the general popula-
tion [74]. But it seems that there are no effects on kidney function and microalbu-
minuria at least in Caucasian population. Blacks and Hispanics may have higher 
risks of hypertension-associated kidney disease after donation [75, 76].
Finally, it is interesting to know that longevity of live donors remains greater 
compared to the general population [24, 72, 77].
7. Conclusion
Living donation is a success story that saved many patients with end-stage renal 
disease from dialysis and offered them a better quality of life and longer life expec-
tancy. Donor surgery has shifted from the old open technique to a mini-invasive 
approach that offers less pain to this category of people who are not true patients 
but true heroes full of courage and nobility. Ensuring the safety and excellent 
long-term outcomes of these donors is our duty, through all steps from preoperative 
workup, surgery, and postoperative care.
Donors must be aware of all potential complications before acceptance and 
should feel free to resign at any moment. Complications of LLDN are present and 
must be prevented by entrusting them to highly qualified and experienced surgeons.
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